StockNews.com Begins Coverage on Syros Pharmaceuticals (NASDAQ:SYRS)

Equities research analysts at StockNews.com assumed coverage on shares of Syros Pharmaceuticals (NASDAQ:SYRS) in a research note issued to investors on Sunday. The brokerage set a “sell” rating on the stock.

A number of other brokerages also recently issued reports on SYRS. JMP Securities restated a “market perform” rating on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. Brookline Capital Management reiterated a “hold” rating on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. TD Cowen reissued a “hold” rating on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th. Finally, HC Wainwright reaffirmed a “neutral” rating and set a $1.00 price target (down previously from $6.00) on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and one has issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $3.33.

Syros Pharmaceuticals Stock Performance

SYRS stock opened at $0.17 on Friday. The company has a market capitalization of $4.49 million, a P/E ratio of -0.06 and a beta of 1.29. Syros Pharmaceuticals has a 52-week low of $0.16 and a 52-week high of $7.96. The company has a fifty day moving average price of $0.22 and a 200-day moving average price of $1.53.

Insider Buying and Selling at Syros Pharmaceuticals

In other news, Director Nancy A. Simonian sold 134,713 shares of the company’s stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $0.27, for a total value of $36,372.51. Following the completion of the transaction, the director now directly owns 41,070 shares of the company’s stock, valued at $11,088.90. This represents a 76.64 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Company insiders own 12.26% of the company’s stock.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Syros Pharmaceuticals stock. GSA Capital Partners LLP acquired a new stake in Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 15,905 shares of the company’s stock, valued at approximately $34,000. GSA Capital Partners LLP owned 0.06% of Syros Pharmaceuticals at the end of the most recent quarter. Hedge funds and other institutional investors own 91.47% of the company’s stock.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.